Excelsior Medical Co., Ltd. (4104.TW)
TWD 84.9
(6.26%)
TWD 84.9
(6.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 236.82 Million TWD | 30.09% |
| 2022 | 182.05 Million TWD | -13.22% |
| 2021 | 209.78 Million TWD | -6.95% |
| 2020 | 225.45 Million TWD | 37.11% |
| 2019 | 164.43 Million TWD | 0.0% |
| 2018 | - TWD | -100.0% |
| 2017 | 49.5 Million TWD | -84.52% |
| 2016 | 319.83 Million TWD | -40.4% |
| 2015 | 536.62 Million TWD | 2960.84% |
| 2014 | 17.53 Million TWD | 7.42% |
| 2013 | 16.32 Million TWD | -95.07% |
| 2012 | 331.2 Million TWD | -54.76% |
| 2011 | 732.1 Million TWD | 66.52% |
| 2010 | 439.65 Million TWD | 334.41% |
| 2009 | 101.2 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 57 Thousand TWD | 0.0% |
| 2024 Q2 | 265.79 Million TWD | -100.0% |
| 2023 Q4 | 236.82 Million TWD | -1.6% |
| 2023 FY | 236.82 Million TWD | 30.09% |
| 2023 Q1 | 170.96 Million TWD | -6.09% |
| 2023 Q2 | 186.07 Million TWD | 8.84% |
| 2023 Q3 | 240.67 Million TWD | 29.34% |
| 2022 Q4 | 182.05 Million TWD | -26.41% |
| 2022 FY | 182.05 Million TWD | -13.22% |
| 2022 Q2 | 233.43 Million TWD | -2.38% |
| 2022 Q1 | 239.13 Million TWD | 13.99% |
| 2022 Q3 | 247.39 Million TWD | 5.98% |
| 2021 FY | 209.78 Million TWD | -6.95% |
| 2021 Q3 | 176.45 Million TWD | -8.47% |
| 2021 Q4 | 209.78 Million TWD | 18.89% |
| 2021 Q1 | 208.33 Million TWD | -7.6% |
| 2021 Q2 | 192.77 Million TWD | -7.47% |
| 2020 Q3 | 221.81 Million TWD | -10.16% |
| 2020 Q4 | 225.45 Million TWD | 1.64% |
| 2020 FY | 225.45 Million TWD | 37.11% |
| 2020 Q2 | 246.9 Million TWD | -4.47% |
| 2020 Q1 | 258.44 Million TWD | 57.17% |
| 2019 Q3 | 184.72 Million TWD | -18.76% |
| 2019 Q2 | 227.37 Million TWD | -6.31% |
| 2019 Q1 | 242.68 Million TWD | 0.0% |
| 2019 Q4 | 164.43 Million TWD | -10.98% |
| 2019 FY | 164.43 Million TWD | 0.0% |
| 2018 Q2 | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 FY | - TWD | -100.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2017 Q3 | - TWD | -100.0% |
| 2017 FY | 49.5 Million TWD | -84.52% |
| 2017 Q4 | - TWD | 0.0% |
| 2017 Q2 | 18.75 Million TWD | -23.57% |
| 2017 Q1 | 24.53 Million TWD | -92.33% |
| 2016 Q2 | 333.8 Million TWD | -15.49% |
| 2016 Q1 | 394.97 Million TWD | -26.4% |
| 2016 FY | 319.83 Million TWD | -40.4% |
| 2016 Q4 | 319.83 Million TWD | -0.3% |
| 2016 Q3 | 320.79 Million TWD | -3.9% |
| 2015 FY | 536.62 Million TWD | 2960.84% |
| 2015 Q1 | 313.14 Million TWD | 1686.12% |
| 2015 Q4 | 536.62 Million TWD | -8.3% |
| 2015 Q2 | 311.5 Million TWD | -0.52% |
| 2015 Q3 | 585.18 Million TWD | 87.86% |
| 2014 FY | 17.53 Million TWD | 7.42% |
| 2014 Q2 | 7.85 Million TWD | -24.15% |
| 2014 Q3 | 20.82 Million TWD | 165.07% |
| 2014 Q4 | 17.53 Million TWD | -15.83% |
| 2014 Q1 | 10.36 Million TWD | -36.52% |
| 2013 Q3 | 15.97 Million TWD | -95.2% |
| 2013 Q4 | 16.32 Million TWD | 2.14% |
| 2013 FY | 16.32 Million TWD | -95.07% |
| 2013 Q2 | 332.83 Million TWD | -1.01% |
| 2013 Q1 | 336.24 Million TWD | 1.52% |
| 2012 Q1 | 731.9 Million TWD | -0.03% |
| 2012 FY | 331.2 Million TWD | -54.76% |
| 2012 Q4 | 331.2 Million TWD | -55.35% |
| 2012 Q3 | 741.74 Million TWD | -0.06% |
| 2012 Q2 | 742.22 Million TWD | 1.41% |
| 2011 Q3 | 732.26 Million TWD | 68.09% |
| 2011 Q1 | 437.62 Million TWD | -0.46% |
| 2011 Q2 | 435.63 Million TWD | -0.45% |
| 2011 Q4 | 732.1 Million TWD | -0.02% |
| 2011 FY | 732.1 Million TWD | 66.52% |
| 2010 Q4 | 439.65 Million TWD | 0.0% |
| 2010 FY | 439.65 Million TWD | 334.41% |
| 2009 FY | 101.2 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Medical Corp. | 141.16 Million TWD | -67.766% |
| OK Biotech Co., Ltd. | 94.1 Million TWD | -151.659% |
| Applied BioCode Corporation | 18.07 Million TWD | -1210.04% |